Giant cell arteritis: epidemiology, diagnosis, prognosis

Authors

  • V.Z. Netiazhenko corresponding member in NAMS of Ukraine, MD, PhD, Head of the Department of propaedeutics internal medicine 1, Bogomolets National Medical University, Kyiv, Ukraine, е-mail: vnetyiazhenko@ukr.net
  • O.G. Puzanova MD, PhD, Professor at the Department of internal and occupational diseases, Private Higher Education Institution “Kyiv Medical University”, Kyiv, Ukraine; e-mail: vizhankova@gmail.com; phone: +380-50-383-23-00

DOI:

https://doi.org/10.22141/2224-1507.9.2.2019.172121

Keywords:

giant cell arteritis, large vessel vasculitis, epidemiology, diagnosis, prognosis

Abstract

Giant cell arteritis (GCA) is the most common systemic vasculitis affecting large vessels in subjects over 50 years old. This di­sease is associated with an increased risk of other inflammatory disea­ses and vascular conditions. Many studies and guidelines focus on sol­ving GCA-associated problems. The aim of this paper is to perform an analytical review, systematic generalization and discussion of evidence on various epidemiological GCA aspects, modern approaches and me­thods of its diagnosis as well as risk factors of unfavorable prognosis.

Downloads

Download data is not yet available.

References

Jenette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013 Jan;65(1):1-11. doi: 10.1002/art.37715.

Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessels vasculitis in clinical practice. Ann Rheum Dis. 2018 May;77(5):636-643. doi: 10.1136/annrheumdis-2017-212649.

Baslund B, Helleberg M, Faurschou M, Obel N. Mortality in patients with giant cell arteritis. Rheuma-tology (Oxford). 2015 Jan;54(1):139-143. doi: 10.1093/rheumatology/keu303.

de Boysson H, Liozon E, Lariviere D, et al. Giant cell arteritis-related stroke: a retrospective multicenter case-control study. J Rheum. 2017;44(3):297-303. doi: 10.3899/jrheum.161033.

Crow RW, Katz BJ, Warner JE, et al. Giant Cell Arteritis and Mortality. J Gerontol A Biol Sci Med Sci. 2009 Mar;64(3):365-369. doi:10.1093/gerona/gln030.

González-Gay MA, Pina T. Giant Cell Arteritis and Polymyalgia Rheumatica: an Update. Curr Rheu-matol Rep. 2015 Feb;17(2):6. doi: 10.1007/s11926-014-0480-1.

Sigl M, Hsu E, Scheffel H, Haneder S, Rümenapf G, Amendt K. Lower extremity vasculitis in giant cell arteritis: important differential diagnosis in patient with lower limb claudication. Vasa. 2014 Sep;43(5):326-336. doi: 10.1024/0301-1526/a000370.

Udayakumar PD, Crowson CS, Warrington KJ, Matteson EL. Incidence of giant cell arteritis in the cur-rent era of advanced diagnostic imaging. Ann Rheum Dis. 2013;72(Suppl 3):FRI0353. doi: 10.1136/annrheumdis-2013-eular.1480.

Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of giant cell arte-ritis. Rheumatology (Oxford). 2010;49:1594-1597. doi: 10.1093/rheumatology/keq039a.

Bienvenu B, Ly KH, Lambert M, et al. Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). Rev Med Intern. 2016;37(3):154-165. doi: 10.1016/j.revmed.2015.12.015.

Beketova TV, Satybaldyev AM, Denisov LN. International guidelines for the management of giant cell arteritis and polymyalgia rheumatica: The 2015 results. Nauchno-prakticheskaya revmatologiya. 2016;54(4):390-394. doi: 10.14412/1995-4484-2016-390-394.

Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review. JAMA. 2016 Jun;315(22):2442-2458. doi: 10.1001/jama.2016.5444.

Guevara M, Kollipara CS. Recent Advances in Giant Cell Arteritis. Curr Rheumatol Rep. 2018 Apr 2;20(5):25. doi: 10.1007/s11926-018-0737-1.

Kermani TA, Schäfer VS, Crowson CS, et al. Increase in age at onset of giant cell arteritis: a population-based study. Ann Rheum Dis. 2010 Apr;69(4):780-781. doi: 10.1136/ard.2009.111005.

Koster MJ, Matteson EL, Warrington KJ. Large-vessel giant cell arteritis: diagnosis, monitoring and management. Rheumatology. 2018;57:ii32-ii42. doi: 10.1093/rheumatology.kex424.

Levine SM, Hellmann DB. Giant cell arteritis. Curr Opin Rheumatol. 2002 Jan;14(1):3-10.

Nesher G, Breuer SG. Giant Cell Arteritis and Polymyalgia Rheumatica: 2016 Update. Rambam Mai-monides Med. 2016;7(4):e0035. doi: 10.5041/RMMJ.10262.

Ness T, Bley TA, Schmidt WA, Lamprecht P. The Diagnosis and Treatment of Giant Cell Arteritis. Dtsch Arztebl Int. 2013 May;110(21):376-386. doi: 10.3238/arztebl.2013.0376.

Watanabe R, Hilhorst M, Zhang H, et al. Glucose metabolism controls disease-specific signatures of macrophage effector functions. JCI Insight. 2018 Oct 18;3(20). pii: 123047. doi: 10.1172/jci.insight.123047.

Laviriere D, Sacre K, Klein I, et al. Extra- and intracranial cerebral vasculitis in giant cell arteritis: an observational study. Medicine (Baltimore). 2014 Dec;93(28):e265. doi: 10.1097/MD.0000000000000265.

Chen JJ, Leavitt JA, Fang C, et al. Evaluating the Incidence of Arteritic Ischemic Optic Neuropathy and Other Causes of Vision Loss from Giant Cell Arteritis. Ophthalmology. 2016 Sep;123(9):1999-2003. doi: 10.1016/j.ophtha.2016.05.008.

Machado EB, Michet CJ, Ballard DJ, et al. Trends in incidence and clinical presentations of temporal arteritis in Olmsted County, Minnesota, 1950-1985. Arthritis Rheum. 1988 Jun;31(6):745-749.

Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Mortality of large-artery complications (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with gi-ant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 2003 Dec;48(12):3532-7. doi: 10.1002/art.11480.

Machado EB, Gabriel SE, Beard CM, Michet CJ, O’Fallon WM, Ballard DJ. A population-based case-control study of temporal arteritis: evidence for an association between temporal arteritis and degenera-tive vascular disease? Int J Epidemiol. 1989 Dec;18(4):836-841. doi: 10.1093/ije/18.4.836.

Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011 Mar;63(3):633-639. doi: 10.1002/art.30155.

Stellingwerff MD, Brouwer E, Lensen KJ, et al. Different Scoring Methods of FDG PET/CT in Giant Cell Arteritis: Need for Standardization. Medicine (Baltimore). 2015 Sep;94(37):e1542. doi: 10.1097/MD.0000000000001542.

Genda E, Oyoo O, Adebajo A. Vasculitis in Africa. Curr Rheumatol Rep. 2018 Feb 21;20(2):4. doi: 10.1007/s11926-018-0711-y.

Watts RA, Scott DG. Epidemiology of vasculitis. In: Ball GV, Fessler BJ, Bridges SL, eds. Oxford text-book of vasculitis. 3rd ed. Oxford: Oxford University Press; 2014. 7-28 pp. doi: 10.1093/med/9780199659869.003.0002.

Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Incidence and Predic-tors of Large-Artery Complication (Aortic Aneurysm, Aortic Dissection, and/or Large-Artery Stenosis) in Patients with Giant Cell Arteritis: A Population-Based Study Over 50 Years. Arthritis Rheum. 2003 Dec;48(12):3522-31. doi: doi.org/10.1002/art.11353.

Hellmich B. Management der Polymyalgia rheumatica und der Großgefäßvaskulitiden. Internist (Berl). 2016 Nov;57(11):1069-1078. doi: 10.1007/s00108-016-0131-x.

Petri H, Nevitt A, Saesour K, Napalkov P, Collinson N. Incidence of giant cell arteritis and characteris-tics of patients: data-driven analysis of comorbidities. Arthritis Care Res (Hoboken). 2015 Mar;67(3):390-395. doi: 10.1002/acr.22429.

Lensen KD, Voskuyl AE, van der Laken CS, et al. 18F-fluorodeoxyglucose positron emission tomogra-phy in elderly patients with elevated erythrocyte sedimentation rate of unknown origin. PloS One. 2013;8(3):e58917. doi: 10.1371./journal.pone.0058917.

Hill CL, Black RJ, Nossent JC, et al. Risk of mortality in patients with giant cell arteritis. Semin Arthritis Rheum. 2017;46(4):513-519. doi: 10.1016/j.semarthrit.2016.08.015.

Evans JM, O’Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med. 1995 Apr 1;122(7):502-7.

Mackie SL, Hensor EM, Morgan AW, Pease CT. Should I send my patient with previous giant cell arte-ritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis. Ann Rheum Dis. 2014;73(1):143-148. doi: 10.1136/annrheumdis-2012-202145.

Robson JC, Kiran A, Maskell J, et al. The relative risk of aortic aneurysm in patient with giant cell arte-ritis compared with the general population of the UK. Ann Rheum Dis. 2015;74(1):129-135. doi: 10.1136/annrheumdis-2013-204113.

Kermani TA, Warrington KJ, Crowson CS, et al. Large Vessel Involvement in Giant Cell Arteritis: A Population-Based Cohort Study of the Incidence-Trends and Prognosis. Ann Rheum Dis. 2013;72(12):1989-1994. doi: 10.1136/annrheumdis-2012-202408.

Matteson EL, Buttgereit F, Dejaco C, Dasgupta B. Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis. Rheum Dis Clin North Am. 2016 Feb;42(1):75-90, viii. doi: 10.1016/j.rdc.2015.08.009.

Laviriere D, Benali K, Coustet B, et al. Positron emission tomography and computed tomography for the diagnosis of giant cell arteritis. A real-life prospective study. Medicine (Baltimore). 2016 Jul;95(30):e4146. doi: 10.1097/MD.0000000000004146.

Alsolaimani RS, Bhavsar SV, Khalidi NA, et al. Severe intracranial involvement in giant cell arteritis: 5 cases and literature review. J Rheumatol. 2016 Mar;43(3):648-656. doi: 10.3899/jrheum.150143.

Ungprasert P, Wijampreecha K, Koster MJ, Thongprayoon C, Warrington KJ. Cerebrovascular accident in patients with giant cell arteritis: A systematic review and meta-analysis of cohort studies. Semin Ar-thritis Rheum. 2016 Dec;46(3):361-366. doi: 10.1016/j.semarthrit.2016.07.005.

Ungprasert P, Koster MJ, Warrington KJ. Coronary artery disease in giant cell arteritis: a systematic re-view and meta-analysis. Semin Arthritis Rheum. 2015;44(5):586-591. doi: 10.1016/j.semarthrit.2014.10.010.

Ungprasert P, Thongprayoon C, Kittonamingkolchai W, Srivali N, Cheungpasitporn W. Peripheral arte-rial disease in patients with giant cell arteritis: a meta-analysis. Int J Rheum Dis. 2016 Aug;19(8):819-825. doi: 10.1111/1756-185X.12631.

Ungprasert P, Sanguankeo A, Upala S, Knight EL. Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014 Dec;44(3):366-370. doi: 10.1016/j.semarthrit.2014.06.004.

Ungprasert P, Upala S, Sanguankeo A, Warrington KJ. Patients with giant cell arteritis have a lower prevalence of diabetes mellitus: a systematic review and meta-analysis. Mod Rheumatol. 2016;26(3):410-414. doi: 10.3109/14397595.2015.1081722.

Li L, Neogi T, Jick S. Giant cell arteritis and vascular diseases − risk factors and outcomes: a cohort study using UK Clinical Practice Research Datalink. Rheumatology (Oxford). 2017 May;56(5):753-762. doi: 10.1093/rheumatology/kew482.

Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for classification of giant cell arteritis. Arthritis Rheum. 1990 Aug;33(8):1122-1128. doi: 10.1002/art.1780330810.

Lie JT. Aortic and extracranial large vessel giant cell arteritis: a review of 72 cases with histological documentation. Semin Arthritis Rheum. 1995;24(6):422-431.

Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 1999 Feb;42(2):311-317. doi: https://doi.org/10.1002/1529-0131(199902)42:2<311::AID-ANR14>3.0.CO;2-F

Muratore F, Kermani TA, Crowson CS, et al. Large-vessel giant cell arteritis: a cohort study. Rheuma-tology (Oxford). 2015;54(3):463-470. doi: 10/1093/rheumatology/keu329.

Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA. 2002;287(1):92-101. doi: 10.1001/jama.287.1.92.

Ghinoi A, Pipitone N, Nicolini A, et al. Large-vessel involvement in recent-onset giant cell arteritis: a case-control colour-Doppler sonography study. Rheumatology (Oxford). 2012 Apr;51(4):730-734. doi: 10.1093/rheumatology/ker329.

Bongartz T, Matteson EL. Large vessel involvement in giant cell arteritis. Curr Opin Rheumatol. 2006;18(1):10-17.

Maksimovicz-McKinnon K, Clark TM, Hoffmann GS. Takayasu arteritis and giant cell arteritis: a spec-trum within the same disease? Medicine (Baltimore). 2009;88(4):221-226. doi: 10.1097/MD.0b013e3181af70c1.

Schmidt WA, Seifert A, Gromnica-Ihle E, Krause A, Natusch A. Ultrasound of proximal upper extremi-ty arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology (Oxford). 2008;47(1):96-101. doi: 10.1093/rheumatology/kem322.

Weyand CM, Goronzy JJ. Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;371(1):50-57. doi: 10.1056/NEJMcp1214825.

Cavazza A, Muratore F, Boiardi L, et al. Inflamed temporal artery: histologic findings in 354 biopsies, with clinical correlations. Am J Surg Pathol. 2014 Oct;38(10):1360-1370. doi: 10.1097/PAS.0000000000000244.

Kermani TA, Matteson EL, Hunder GG, Warrington KJ. Symptomatic Lower Extremity Vasculitis in Giant Cell Arteritis: a Case Series. J Rheumatol. 2009 Oct;36(10):2277-2283. doi: 10.3899/rheum.090269.

Alba MA, Garcia-Martinez A, Prieto-Gonzáles S, et al. Relapses in patients with giant cell arteritis: prev-alence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 pa-tients. Medicine (Baltimore). 2014 Jul;93(5):194-201. doi: 10.1097/MD.0000000000000033.

Restuccia G, Boiardi L, Cavazza A, et al. Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-Term Follow-Up Study. Medicine (Baltimore). 2016 May;95(19):e3524. doi: 10.1097/MD.0000000000003524.

Restuccia G, Boiardi L, Cavazza A, et al. Long-term remission in biopsy-proven giant cell arteritis: a ret-rospective cohort study. J Autoimmun. 2017 Feb;77:39-44. doi: 10.1016/j.jaut.2016.10.002.

Martinez-Lado L, Calviño-Diaz C, Piñeiro A, et al. Relapses and recurrenceses in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine (Baltimore). 2011 May;90(3):186-193. doi: 10.1097/MD.0b013e31821c4fad.

Labarca С, Koster MJ, Crowson CS, et al. Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. Rheumatology (Oxford). 2016 Feb;55(2):347-356. doi: 10.1093/rheumatology/kev348.

Kermani TA, Crowson CS, Muratore F, Schmidt J, Matteson EL, Warrington KJ. Extra-cranial giant cell arteritis and Takayasu arteritis: How similar are they? Semin Arthritis Rheum. 2015;44(6):724-728. doi: 10.1016/jseminarthrit.2015.01.005.

Schmidt WA. Role of ultrasound in the understanding and management of vasculitis. Ther Adv Muscu-loskelet Dis. 2014;6(2):39-47. doi: 10.1177/1759720X13512256.

Koster MJ, Warrington KJ. Classification of large vessel vasculitis. Can we separate giant cell arteritis from Takayasu arteritis? Presse Med. 2017 Jul - Aug;46(7-8 Pt 2):e205-e213. doi: 10.1016/j.lpm.2016.11.032.

Futura S, Cousins C, Chaudhry A. Clinical features and radiological findings in large vessel vasculitis: are Takayasu arteritis and giant cell arteritis 2 different diseases or a single entity? J Rheumatol. 2015;42(2):300-308. doi: 10.3899/jrheum.140562.

Blockmans D, de Ceuninck DL, Vanderschüren S, Knockärt D, Mortelmans L, Bobbärs H. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum. 2006;55(1):131-137. doi: 10.1002/art.21699.

Agard C, Barrier JH, Dupas B, et al. Aortic involvement in recent-onset giant cell (temporal) arteritis: a case-control prospective study using helical aortic computed tomodensitometric scan. Arthritis Rheum. 2008;59(5):670-676. doi: 10.1002/art.23577.

Prieto-González S, Arguis P, Garsia-Martinez A, et al. Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. Ann Rheum Dis. 2012;71(7):1170-1176. doi: 10.1136/annrheumdis-2011-200865.

Prieto-González S, Depetris M, Garsia-Martinez A, et al. Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed biopsy-proven giant cell arteritis: a prospec-tive, case-control study. Ann Rheum Dis. 2014;73(7):1388-1392. doi: 10.1136/annrheumdis-2013-204572.

García-Martínez A, Hernández-Rodríguez J, Arguis P, et al. Development of aortic aneurysm / dilatation during the follow-up of patients with giant cell arteritis: a cross-sectional screening of fifty-four pro-spectively followed patients. Arthritis Rheum. 2008;59(3):422-430. doi: 10.1002/art.23315.

Mekinian A, Djelbani S, Viry F, Fain O, Soussan M. Usefulness of imaging in large vessel vasculitis. Rev Med Interne. 2016;37(4):245-255. doi: 10.1016/j.revmed.2015.10.353.

Lensen KD, Voskuyl AE, Comans EF, van der Laken CJ, Smulders YM. Extracranial giant cell arteritis: A narrative review. Neth J Med. 2016;74(5):182-192.

Schmidt J, Duhaut P. Aortitis in giant cell arteritis. Rev Med Interne. 2016;37(4):239-244. doi: 10.1016/j.revmed.2015.12.018.

Lee YH, Choi SJ, Ji JD, Song GG. Diagnostic accuracy of 18F-FDG PET or PET/CT for large vessel vasculitis : A meta-analysis. Z Rheumatol. 2016;75(9):924-931. doi: 10.1007/s00393-015-1674-2.

Besson FL, Parienti JJ, Bienvenu B. Diagnostic perfomance of 18F-fluorodeoxyglucose positron emis-sion tomography in giant cell arteritis: a systematic review and meta-analysis. Eur J Nucl Med. 2011;38(9):1764-1772. doi: 10.1007/s00259-011-1830-0.

Soussan M, Nicolas P, Schramm C, et al. Management of large-vessel vasculitis with FDG-PET: a sys-tematic literature review and meta-analysis. Medicine (Baltimore). 2015;94:e622. doi: 10.1097/MD.0000000000000622.

Schmidt, WA, Moll A, Seifert A, Schicke B, Gromnica-Ihle E, Krause A. Prognosis of large-vessel giant cell arteritis. Rheumatology (Oxford). 2008;47(9):1406-1408. doi: 10.1093/rheumatology/ken258.

Diamantopulos AP, Haugeberg G, Hetland H, Soldal DM, Bie R, Myklebust G. Diagnostic value of col-our Doppler ultrasonography of temporal arteries and large vessels in giant cell arteritis: a consecutive case series. Arthritis Care Res (Hoboken). 2014;66(1):113-119. doi: 10.1002/acr.22178.

Prieto-González S, Terrades-Garsia N, Corbera-Bellalta M, et al. Serum osteopontin: a biomarker of dis-ease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical use-fulness in tocilizumab-treated patients. RMD Open. 2017 Dec;3(2):e000570. doi: 10.1136/rdmopen-2017-000570.

Prieto-González S, Garsia-Martinez A, Tavera-Bahillo I, et al. Effect of glucocorticoid treatment on computer tomography angiography detected large vessel inflammation in giant cell arteritis. A prospec-tive, longitudinal study. Medicine (Baltimore). 2015 Feb;94(5): e486. doi: 10.1097/MD.0000000000000486.

Published

2021-09-24

How to Cite

Netiazhenko, V., & Puzanova, O. (2021). Giant cell arteritis: epidemiology, diagnosis, prognosis. PAIN, JOINTS, SPINE, 9(2), 90–107. https://doi.org/10.22141/2224-1507.9.2.2019.172121

Issue

Section

Reviews